Coherus Biosciences Inc CHRS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Anicetti Vincent R

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,500

Price:

--
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Anicetti Vincent R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,500

Price:

$17.94
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Anicetti Vincent R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,500

Price:

$2.50
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Wahlstrom Mats

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Healy James

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Szela Mary T

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Tzoumakas Kimberly Jo

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Nussbaum Samuel R Md

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Lawlis V Bryan

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Vexler Vladimir

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

62,500

Price:

--

Filings by filing date

Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Anicetti Vincent R

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,500

Price:

--
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Anicetti Vincent R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,500

Price:

$17.94
Jan 19, 2021 (filed on Jan 21, 2021)

Insider Name:

Anicetti Vincent R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,500

Price:

$2.50
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Wahlstrom Mats

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Healy James

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Szela Mary T

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Tzoumakas Kimberly Jo

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Nussbaum Samuel R Md

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Lawlis V Bryan

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

20,000

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Vexler Vladimir

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

62,500

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	333 Twin Dolphin Dr Ste 600 REDWOOD CITY CA 94065-1442
Tel:	N/A
Website:	https://www.coherus.com
IR:	See website

Key People

Dennis M. Lanfear Chairman of the Board, President, Chief Executive Officer	Jean-Frederic Viret Chief Financial Officer	Vincent R. Anicetti Chief Operating Officer
Vladimir Vexler Chief Scientific Officer	Thomas Fitzpatrick Chief Legal Officer

Business Overview

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Financial Overview

For the nine months ended 30 September 2020, CoherusBiosciences Inc revenues increased 57% to $365.4M. Netincome increased from $50.6M to $122.5M. Revenues reflectan increase in demand for the Company's products andservices due to favorable market conditions. Net incomebenefited from General and administrative decrease of 2% to$83.8M (expense), Stock-based Compensation in R&D decreaseof 1% to $10.3M (expense).

Employees:	306 as of Sep 30, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,222M as of Sep 30, 2020
Annual revenue (TTM):	$489.26M as of Sep 30, 2020
EBITDA (TTM):	$188.14M as of Sep 30, 2020
Net annual income (TTM):	$161.76M as of Sep 30, 2020
Free cash flow (TTM):	$132.07M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	72,048,012 as of Oct 31, 2020
Index Membership:	S&P 600 Small Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Coherus Biosciences Inc (OQ:CHRS)